FocusMesothelioma

A New Hope for Precision Medicine

Science Translational Medicine  23 Oct 2013:
Vol. 5, Issue 208, pp. 208fs38
DOI: 10.1126/scitranslmed.3007622

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Abstract

The SS1P immunotoxin is combined with immunomodulatory therapy in order to improve its efficacy in human mesothelioma (Hassan et al., this issue).

View Full Text